NCT00300339 (MASCOT) is a Phase 2 clinical trial of SL650472, Clopidogrel in Intermittent Claudication, sponsored by Sanofi.

Who is sponsoring NCT00300339?

NCT00300339 is sponsored by Sanofi.

What drugs are being tested in NCT00300339?

Interventions in NCT00300339: SL650472, Clopidogrel.

What condition does NCT00300339 study?

NCT00300339 studies Intermittent Claudication.

Is NCT00300339 still recruiting?

NCT00300339 is currently completed. Last updated 18 December 2008.

Last reviewed 2008-12-18 · How we verify

NCT00300339: MASCOT

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Double-Blind, Double-Dummy, Randomized, Parallel Group Trial of SL650472 (Three Dose Regimens Versus Placebo and Cilostazol), for 24-Week Improvement of Walking Distance in Patients With Stage II Peripheral Arterial Disease Who Benefit From Optimal Prevention Strategy Including Clopidogrel

Completed Phase 2 Last updated 18 December 2008

What this trial tests

Phase 2 trial testing SL650472, Clopidogrel in Intermittent Claudication in 599 participants. Completed in 1 December 2007.

Timeline

1 February 2006

Primary endpoint
1 December 2007

1 December 2007

Quick facts

Lead sponsor	Sanofi
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	599
Start date	1 February 2006
Primary completion	1 December 2007
Estimated completion	1 December 2007
Sites	9 locations across United States, Belgium, Canada, Czechia, Germany, Mexico, Russia, Sweden

Drugs / interventions tested

SL650472, Clopidogrel — full drug profile →

Conditions studied

Intermittent Claudication — all drugs for Intermittent Claudication →

Sponsor

Sanofi — full company profile →

Who can join

40 and older, any sex, with Intermittent Claudication. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Primary: percent change in initial claudication distance (ICD) measured at the 24-week test, compared with that at baseline

Sponsor's own description

To investigate in patients suffering from intermittent claudication due to Fontaine stage II PAD whether a 24-week treatment by SL650472 OD on top of clopidogrel may result in an improvement of walking capacity, by comparing three doses of SL650472 to placebo, and to calibrate such effect versus cilostazol

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Cilostazol for intermittent claudication.
Brown T, Forster RB, Cleanthis M, Mikhailidis DP, et al · · 2021 · cited 29× · PMID 34192807 · DOI 10.1002/14651858.cd003748.pub5

Verify or expand the search:

Other recruiting trials for Intermittent Claudication

Currently open trials in the same condition.

NCT06686121 — Improving Mobility After Revascularization in Peripheral Artery Disease · Phase 3 · recruiting
NCT06657976 — Response to Exercise and Nitric Oxide in PAD · Phase 2 · recruiting
NCT05457738 — Home-based Exercice Therapy for Patients With Intermittent Claudication Using a New Smartphone Application · NA · recruiting
NCT06114732 — Motivating Physical Activity With Behavioural interVention and Electrical Stimulation Remotely in Intermittent Claudicat · NA · recruiting
NCT05132439 — MetfOrmin BenefIts Lower Extremities With Intermittent Claudication · Phase 3 · recruiting

Other Sanofi trials

Trials by the same sponsor.

NCT07282795 — Post-marketing Surveillance Study for the Safety of Efluelda® Pre-filled Syringe · not yet recruiting
NCT06694025 — Post-marketing Surveillance Study for the Safety of Efluelda Tetra Pre-filled Syringe. · not yet recruiting
NCT07222189 — A Study to Investigate the Long-term Safety, Tolerability and Efficacy of Balinatunfib in Participants With Crohn's Dise · Phase 2 · not yet recruiting
NCT07484230 — A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Adult Japanese Partic · Phase 3 · not yet recruiting
NCT07547436 — A Study to Access Activity and Safety With SAR445399 Compared With Placebo in Participants Aged 18 to 80 Years of Age Wi · Phase 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00300339 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Sanofi
Last refreshed: 18 December 2008

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00300339.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing